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Abstract. In this study we investigated the cerebrospinal fluid (CSF) levels of neurofilament light (NFL) and heavy chain
(NFHp35), total tau (t-tau), and glial fibrillary acidic protein (GFAP) to detect disease specific profiles in sporadic Creutzfeldt
Jakob disease (sCJD) patients and Alzheimer’s disease (AD) patients. CSF levels of NFL, NFHp35, t-tau, and GFAP of 23
sCJD patients and 55 AD patients were analyzed and compared to non-demented controls. Median NFL, NFHp35, GFAP, and
t-tau levels were significantly increased in sCJD patients and AD patients versus controls (p < 0.0001 in all). NFL, NFHp35,
and t-tau levels were significantly increased in sCJD patients versus AD patients (p < 0.005), but GFAP concentrations did not
differ between sCJD and AD. The results suggest that neuroaxonal damage, reflected by higher CSF levels of NFL, NFHp35, and
t-tau, is more pronounced in the pathophysiology of sCJD than in AD. The comparable CSF GFAP concentrations suggest that
astroglial damage or astrocytosis is equally pronounced in the pathophysiology of AD and sCJD. Prospective studies are needed
to determine whether NFL and NFHp35 may be additional tools in the differential diagnosis of rapidly progressive dementias.
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INTRODUCTION
Alzheimer’s disease (AD) is a devastating neu-
rodegenerative disorder characterized by widespread
loss of cortical neurons and their connections result-
ing in memory loss and cognitive decline. Sporadic
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Creutzfeldt-Jakob disease (sCJD) is a rare, fatal neu-
rodegenerative disorder, belonging to the spongiform
encephalopathies which is clinically characterized by
a rapidly progressive dementia with visual or cerebel-
lar signs, (extra)pyramidal symptoms, and ultimately
akinetic mutism.
In AD, the typical cerebrospinal fluid (CSF) pattern
includes elevated total tau (t-tau) and hyperphospho-
rylated tau (p-tau) proteins, whereas the amyloid-β42
protein (Aβ42) concentration is decreased [1]. In sCJD,
detection of 14-3-3 protein is highly sensitive and is
part of the WHO diagnostic criteria for sCJD [2], and
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strongly elevated levels of t-tau protein are highly spe-
cific. Other abnormal proteins in CSF of sCJD pa-
tients include elevated S100B and neuron-specific eno-
lase (NSE) and decreased Aβ42 [3,4]. However, CSF
t-tau levels are usually much higher in sCJD than in AD
and Aβ42 levels are usually much lower in AD than in
sCJD.
Neurofilament (NF) proteins are neuronal cytoskele-
ton proteins. They play an important role in neuronal
structure and are mainly located in large myelinated
neurons. NF-proteins are highly phosphorylated and
are composed of 3 subunits defined by their molecular
weight: 68 kDa (NF-light chain, NFL), 160 kDa (NF-
medium chain, NFM), and 200 kDa (NF-heavy chain,
NFH). Elevated CSF levels of NF-proteins have been
found in vascular dementia, AD, and frontotemporal
dementia (FTD) and it was demonstrated that CSF NFL
analysis may help to distinguish FTD from AD [5–7].
NF-protein analysis in sCJD has not been reported so
far, although neuropathological reports on neurofila-
ment inclusions in sCJD suggest neurofilament levels
could be increased in sCJD [8]. In addition, since the
concentration of the glial protein S100B is significantly
increased in CSF of sCJD patients and because of the
reactive astrocytosis in sCJD, it can be speculated that
concentrations of the astrocyte marker glial fibrillary
acidic protein (GFAP) will also be increased in CSF of
sCJD patients.
The aim of the present study was to identify whether
markers of neuronal damage (NFL, NFHp35, t-tau) and
glial damage (GFAP) are abnormal in CSF of sCJD and
AD patients and to determine a disease specific profile.
MATERIALS AND METHODS
Patients
This retrospective study included 23 sCJD patients
and 55 AD patients identified through the CSF databas-
es of the Radboud University Nijmegen Medical Centre
and the Born Bunge Institute (University of Antwerp)
between January 1998 and January 2005. Inclusion in-
to the study was dependent upon the availability of CSF
for additional analyses and of the availability of suffi-
cient clinical information to make a proper diagnosis.
Only patients with a probable diagnosis according to
standard diagnostic criteria were included. The sCJD
patients fulfilled the WHO criteria for probable sCJD
and a diagnosis of probable AD was made according
to the revised NINCDS-ADRDA criteria [2,9]. The
diagnostic examination included physical, neurologi-
cal and mental status examination, screening laborato-
ry tests, routine CSF analysis, and MRI or CT of the
brain. The sCJD patients also underwent EEG. Twenty
probable sCJD patients had converted to definite sCJD
by the time of data analysis. In the remaining 3 prob-
able sCJD patients, postmortem neuropathological ex-
amination had not been allowed by the family. Two
of them were tested for 14-3-3 and were positive; the
other one had not been analyzed for 14-3-3, but had a
typical EEG (with periodic sharp wave complexes) and
died after a total disease duration of 14 months. None
of the sCJD patients survived more than 2 years after
having been diagnosed with sCJD. The sCJD patients
from the Belgian center (n = 15) were also included in
a previous study [10]; the other sCJD patients were not
published previously.
The study contained some missing data, since the
archived CSF was not sufficient for all analyses. The
sCJD patients (n = 23) had all been tested for NFHp35
and t-tau, whereas 21 patients had been tested for NFL
or 14-3-3 and 18 for GFAP. All AD patients (n = 55)
had been tested for NFL and t-tau, whereas 52 had been
tested for NFHp35, 51 for GFAP, and 40 for 14-3-3.
Disease duration at the time of lumbar puncture was
also recorded and available in all patients.
For determination of CSF biomarker concentration
in a control population, non-demented controls were
included with ages between 50–85 years who were re-
ferred to the Department of Neurology of the RUNMC
and underwent a lumbar puncture in a diagnostic work-
up, but who, after extensive examination, turned out
not to have a neurological disease, and who had nor-
mal CSF cell count, hemoglobin, bilirubin, total pro-
tein, lactate, glucose and no oligoclonal IgG bands. For
NFHp35, 21 controls (mean age 57 yr, SD 7.9) were
used. For NFL, 23 controls (mean age 57.6 yr, SD 7.9)
were used, for t-tau 80 controls (mean age 60.2 yr, SD
8.8), and for GFAP 31 controls (mean age 58.7 yr, SD
8.4) were used.
CSF analysis
CSF was obtained by lumbar puncture, collected in
polypropylene tubes, and transferred to the hospital
laboratory within 30 min. Lumbar punctures were per-
formed after informed consent was obtained from the
patient, or from his or her legal representative. Af-
ter routine investigations, CSF was centrifuged (860 g,
5 min), aliquoted and stored at −80◦C until analysis.
The concentrations of t-tau and GFAP were analyzed
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Table 1
Patient characteristics and concentrations of CSF biomarkers
sCJD AD CONT p-value
Number of patients 23 55 130
Gender (m/f) 10/13 23/32 N.S.1
∗Age (yrs) 68.4 (8.2) 68.7 (8.8) 59.2 (8.4) N.S.1; < 0.00012,3
#Duration (months) 5 (2–9.5) 24 (18–40) N.A. < 0.00011
∗MMSE N.A. 19 (5.5) N.A. N.A.
#NFHp35 (ng/L) 579 (420–796) 117 (77–165) 75 (61–88) (n = 21) < 0.00011,2 ; 0.00073
#NFL (ng/L) 78.0 (32.6–123.3) 7.2 (6.0–18.1) 5.20 (0–19.7) (n = 23) < 0.00011,2 ; 0.0443
#GFAP (µg/L) 2.4 (1.3–6.1) 2.9 (2.3–3.7) 1.39 (0.6–2.2) (n = 31) 0.0541; 0.00372; < 0.00013
#Tau (ng/l) 6438 (2400–15230) 593 (388–795) 179 (136–253) (n = 80) < 0.00011,2,3
$14-3-3 20 (n = 21) 5 (n = 40) N.A. < 0.00011
Abbreviations: sCJD, sporadic Creutzfeldt-Jakob disease; AD, Alzheimer’s disease; CONT, non-demented controls; NFL,
neurofilament light chain; NFHp35, phosphorylated neurofilament heavy chain; GFAP, glial fibrillary acidic protein; Tau,
tau-protein.
#Median (25th–75th percentile) are shown. ∗Mean (standard deviation) are shown. $Number of positive tests is shown (total
number of tests). N.S., not significant; N.A., not applicable, n: number. 1sCJD compared to AD, 2sCJD compared to CONT,
3AD compared to CONT. p-values for NFHp35 and NFL; Mann Whitney-tests; p-values for GFAP and t-tau: t-tests.
routinely every two weeks, i.e., at a maximum storage
time at −80◦C of two weeks after sample collection.
GFAP concentrations were analyzed by a homemade
sandwich ELISA as described earlier [11]. The inter-
assay CV% is 8.6% (n = 16; at a concentration of
4.5 µg/L). T-tau concentrations in CSF were analyzed
by using the Innotest hTau assay (Innogenetics, Ghent,
Belgium). The inter-assay CV% is 6.9% (n = 20; at a
concentration of 263 ng/L). Previously described sand-
wich ELISAs were used to determine NFL and NFHp35
levels [12,13]. Both NFL and NFHp35 were retrospec-
tively analyzed in the patient groups after the selection
of the patient groups was completed. The inter-assay
CV for NFL was 3.9% at a concentration of 124 ng/l
(n = 8), 9.1% at a concentration of 60 ng/l (n = 14),
and 17.8% at a concentration of 26 ng/l (n = 15). For
NFHp35, the interassay CV was 18% at a concentration
of 35 ng/L (n = 18). The presence of the 14-3-3 pro-
tein in CSF was routinely determined every two weeks
by electrophoresis and immunoblotting. In brief, CSF
proteins were separated by SDS-PAGE electrophoresis.
Proteins were transferred to nitrocellulose membranes,
after which the membranes were successively incubat-
ed overnight with Odyssey blocking buffer (LI-COR
Biosciences, Lincoln, NE, USA), anti-14-3-3β anti-
body (Santa Cruz Biotech, 2 h) and Alexa Fluor680-
labeled goat anti-rabbit antibodies (1 h). Incubation
steps were each followed by extensive washing in PBS.
Blots were scanned by using Odyssey infrared imaging
system (LI-COR Biosciences), according to manufac-
turer’s instructions. Total protein concentrations were
measured by using the Lowry method.
Statistical analysis
Kolmogorov-Smirnov normality tests showed non-
Gaussian distribution of CSF NFHp35 in the AD and
control groups and of NFL in the AD group. There-
fore, data of NFHp35, NFL, t-tau, and GFAP are all
presented as median and p25–p75 range, and non-
parametric Mann-Whitney tests were used to analyze
non-Gaussian distributed CSF data, whereas t-tests
were used to analyze Gaussian distributed CSF data.
Adjustments for age, gender, disease duration and to-
tal protein concentrations were performed by using lin-
ear regression. Correlations between CSF and clini-
cal parameters were analyzed using the Spearman test
for non-Gaussian distributed variables and the Pearson
test for Gaussian distributed variables; in case of CSF
proteins a partial correlation analysis (by group) was
used. Graphpad Prism (San Diego, CA) and SPSS16.0
software were used for statistical analysis.
RESULTS
Baseline characteristics and biochemical analyses
are summarized in Table 1. All sCJD patients clinically
suffered from a (severe) dementia syndrome. Abnor-
mal triphasic waves on EEG analysis were observed
in 14 patients, absent in 8 patients and could not be
unequivocally determined in one patient. Myoclonic
jerks were observed in 15 patients. Seven sCJD pa-
tients had pyramidal symptoms (spasticity and exten-
sor plantar responses), 9 patients had extrapyramidal
symptoms (hypo/ bradykinesia, chorea or rigidity), 16
patients had a cerebellar syndrome (ataxia) and in only
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Fig. 1. Concentrations of NFHp35 (A), NFL (B), GFAP (C), and tau (D) per patient group. Horizontal lines indicate median levels. Abbreviations:
sCJD, sporadic Creutzfeldt-Jakob disease; AD, Alzheimer’s disease; CONT, controls.
7 sCJD patients typical abnormalities on MRI, e.g., bi-
lateral hyper intense signal on T2 weighted images pre-
dominantly affecting the caudate nucleus and putamen,
were observed.
Levels of CSF NFL, NFHp35, and t-tau were sig-
nificantly increased in sCJD versus controls and sCJD
versus AD patients (Table 1; Fig. 1a, b, d), whereas
total protein concentrations were similar in AD (mean
513 mg/L) and sCJD (mean 495 mg/L; p = 0.75). Sim-
ilar results were obtained after adjustment of the da-
ta for age, gender, disease duration and total protein
concentrations. Also, similar p-values were obtained
if we log-transformed the results for NFL, NFHp35,
t-tau, and GFAP (to normalize the data distribution for
NFL and NFHp35), either with or without adjustment
for age, gender, and disease duration. GFAP levels
were higher in either sCJD or AD versus controls (Ta-
ble 1; Fig. 1c), but did not differ significantly between
sCJD and AD patients (Table 1; Fig. 1c). The differ-
ences in GFAP results between AD and controls, but
not between sCJD and controls, remained significant
after adjustment for age, gender, and disease duration.
Furthermore, the differences between sCJD and AD re-
mained significant in those subgroups (sCJD, n = 17;
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AD, n = 44) for whom all CSF data of NFL, NFHp35,
t-tau, and GFAP were available. The test for the pres-
ence of the 14-3-3 protein in CSF by immunoblotting
was positive in 20 cases with sCJD and 5 cases with
AD (p < 0.0001).
No significant correlation between CSF markers and
either age or disease duration was found in sCJD pa-
tients. In AD patients, we found a weak correlation
between NFL concentration and age (r = 0.297; p =
0.022), but not with disease duration. No other corre-
lations were found between the various CSF markers
and clinical parameters in either sCJD or AD patients.
Correlations between the CSF proteins are shown in
Table 3; significant correlations were observed between
NFH, NFL, and GFAP, between GFAP and t-tau, but
not between t-tau and either NFL or NFH.
The results of the ROC analysis to discriminate AD
from sCJD are shown in Table 2. NFL, NFHp35 and tau
analysis all resulted in a high area under the ROC curve
and high likelihood ratio. Binary (multivariate) logistic
regression analysis selected NFL, NFHp35, tau and
duration as independent contributors for differentiation
between sCJD and AD according to the model: Y =
33.68–0.465 * NFL–0.15 * NFHp35–0.026 * tau +
1.98 * duration (months). The ROC area under curve of
this equation was 0.998 and therefore almost perfectly
discriminated sCJD from AD patients.
DISCUSSION
In this study, we found significantly elevated con-
centrations in CSF of NFHp35, NFL, t-tau, and GFAP
in sCJD and AD compared to controls. Concentrations
of CSF NFL, NFHp35, and t-tau were also significantly
elevated in sCJD compared to AD patients, but GFAP
levels did not differ between these two patient groups.
Both human and animal studies have shown that NF-
proteins play an important role in the axonal environ-
ment. These highly phosphorylated proteins are essen-
tial in maintaining neuronal cytoskeletal plasticity by
influencing axonal caliber and axonal transport [14].
Neuropathological examination in sCJD has shown nu-
merous abnormal neurites labeled by NF-protein im-
munocytochemistry [8]. In previous studies it has been
shown that elevated NFL levels are associated with ax-
onal and white matter damage in neurological diseases
such as multiple sclerosis, FTD, and multiple system
atrophy [7,13,15]. NF-proteins may be regarded as
biomarkers for degeneration of large, myelinated ax-
ons. Our data suggest that these axons are either more
subject to degeneration in sCJD than AD or release
NF-proteins during the course of this disease, which
may lead to the highly elevated CSF concentrations.
A close observation of the NFL data in the AD group
revealed a potential bimodal distribution of the data;
we did not, however, find a correlation with sampling
date or storage time which may explain this difference.
T-tau concentration was also strongly elevated in
sCJD relative to AD. T-tau is a microtubule associated
protein mainly localized in neuronal axons where it has
a function in maintaining the normal cytoskeleton, by
stabilizing microtubules that are essential for axonal
transport. Thus, the high concentration of t-tau in CSF
of sCJD patients also suggests a more compromised ax-
onal function in this disorder. Our data are in line with
previous studies, in which strongly elevated t-tau con-
centrations were reported in CSF of sCJD patients [4,
10,16]. The concentrations of both NFL and t-tau were
increased by a factor 10 in sCJD compared to AD, sug-
gesting, at first sight, that similar pathophysiological
mechanisms may lead to release of these axonal pro-
teins into the CSF of sCJD patients. However, we did
not find a correlation between NFL and t-tau levels, sug-
gesting that independent mechanism contribute to the
release of multiple axonal proteins in the extracellular
space and, eventually, CSF. Furthermore, in previous
studies we found that NFL and t-tau independently con-
tributed to the differentiation of MSA from idiopathic
Parkinson’s disease [13]. Thus, although both NF and
t-tau proteins are both located in axons, these observa-
tions strongly suggest that different pathophysiological
mechanisms lead to the release of these proteins into
the extracellular space. This hypothesis is strengthened
by the observation that the concentrations of NFHp35
in sCJD were elevated by a factor 5 compared to AD
and also did not correlate to t-tau levels. The respective
mechanisms that lead to these differences remain to be
elucidated.
We did not find a significant difference in CSF
GFAP concentration between sCJD and AD and the
GFAP concentration in either group was only marginal-
ly, albeit significantly, increased compared to controls.
GFAP is a cytoskeletal protein of astrocytes which is
important for astrocyte motility and shape. GFAP ex-
pression is increased during reactive astrocytosis, a pro-
cess that is associated with senile plaque formation in
AD brains and that is a common feature of sCJD as
well [17,18]. In a previous study, it was described that
CSF GFAP concentrations were higher in AD than in
sCJD [19]. Our data do not support this observation,
but suggests that the degree of astrocytosis is compa-
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Table 2
ROC analysis of the CSF biomarkers NFL, NFHp35, t-tau, and 14-3-3
CSF parameter Cut-off value Sens % Spec % PPV % NPV % Likelihood ratio AUC (95% CI)
NFL (ng/l) > 29.8 81 91 77 93 4.8 0.93 (0.87–0.99)
NFHp35 (ng/l) > 276.5 90 96 82 98 20.8 0.95 (0.88–1.0)
t-tau (ng/l) > 1072 93 96 85 98 21.7 0.98 (0.94–1.0)
14-3-3 N.A. 95 88 80 97 7.9 0.91 (0.83–0.99)
Abbreviations: NFL, neurofilament light chain; NFHp35, phosphorylated neurofilament heavy chain; t-tau, total tau
protein; Sens, sensitivity; Spec, Specificity; PPV, positive predictive value; NPV, Negative predictive value; AUC, area
under curve. N.A., not applicable.
Table 3
Partial correlation analysis of the CSF proteins NFH,
NFL, GFAP, and t-tau
NFH NFL t-tau
NFL R = 0.473
p < 0.0001
t-tau R = 0.189 R = 0.077
p = 0.147 p = 0.558
GFAP R = 0.350 R = 0.449 R = 0.684
p = 0.006 p < 0.0001 p < 0.0001
R = partial regression coefficient.
rable in sCJD and AD. Interestingly, our correlation
analysis demonstrated a correlation between t-tau and
GFAP, suggesting that reactive astrocytosis is linked to
axonal degeneration. However, given the magnitude of
increase in CSF biomarkers, our observations showed
that in particular neuro-axonal degeneration contributes
to the pathophysiological mechanism of sCJD, rather
than astrocyte degeneration. GFAP expression is lim-
ited to astrocytes, whereas the protein S100B is a more
general marker for the glial cell population in the brain,
also including oligodendrocytes and Schwann cells.
It has been demonstrated previously that the CSF
concentrations of S100B are increased in a majority of
the sCJD patients, but is less pronounced in AD [3].
Therefore, it seems likely that degeneration of oligo-
dendrocytes or Schwann cells, rather than that of astro-
cytes, contributes to the elevated S100B concentration
in sCJD CSF.
The typical findings in CSF of sCJD patients can be
summarized by elevated concentrations of the proteins
14-3-3, t-tau, NSE and S100B. In particular, the diag-
nostic accuracy of the testing for the presence in CSF
of the 14-3-3 protein, as part of the WHO diagnostic
criteria, has been extensively studied. Reported sen-
sitivities to detect sCJD on the basis of 14-3-3 analy-
sis vary between 83% and 100% with a specificity of
67%–100% [16,20–28]. Our data fit in with these num-
bers. A recent autopsy-based study on 280 consecutive
cases clinically suspected of sCJD in the Netherlands,
however, demonstrated a sensitivity of only 74% and
specificity of 79%, demonstrating the limitations of this
biochemical assay [29].
Sensitivity for t-tau varied between 86% and 98%
with a specificity of 75–97% [16,20–22,25]. Sensitiv-
ity to detect sCJD is generally lower for NSE (79%–
85%), with specificities ranging from 85%–92% [22,
23,28]. Finally, sensitivity to detect sCJD by using
S100B quantification in CSF varied between 84% and
98% and specificity widely ranges from 29% to 90% [3,
23,25]. In the light of these findings the combined sen-
sitivity and specificity we report here for t-tau, NFL and
NFHp35 are very well comparable with other biomark-
ers. In the case of t-tau NFHp35 these numbers are at
the high end of reported ranges as are the likelihood
ratios and area under the curves.
It should be noted, however, that the timing of the
lumbar puncture relative to the onset of clinical symp-
toms may affect the diagnostic accuracy of several
biomarkers. It has been reported that the sensitivity for
14-3-3, t-tau, and S100B is higher in patients with a
lumbar puncture taken within 6 weeks after the clin-
ical symptoms compared to a delayed lumbar punc-
ture [25]. Contrasting reports have also been published,
however [30]. Finally, the M/V polymorphism at po-
sition in the PRNP gene may also slightly affect the
diagnostic accuracy of the respective biomarkers [25,
30]. One of the limitations of our study is its retrospec-
tive, unblinded nature which might have confounded
the results by indication. The missing values might
have introduced skewing of data as well; however, giv-
en the major differences we observed in the concentra-
tions of CSF NFL, NFHp35, and t-tau, this effect will
be of minor importance. In conclusion, we found a
disease specific CSF profile of sCJD in which the very
high concentrations of NFL, NFHp35, and t-tau reflect
a more important role of neuroaxonal damage in sCJD
compared to AD. In contrast, astroglial damage seems
to play an equally important role in either sCJD or AD.
Moreover, this study is the first to evaluate analysis of
NF proteins in sCJD-patients. It demonstrated that lev-
els of NFL and NFHp35 are significantly and strongly
increased in sCJD versus AD and controls. The ability
to measure the neurofilament levels quantitatively with
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an ELISA makes this analysis potentially interesting
for diagnostic purposes and has advantages over the
qualitative assessment of 14-3-3 protein in CSF, which
is performed by immunoblotting. Assessment of the
potential of NF protein analysis as an additional di-
agnostic value in rapidly progressive dementias awaits
future prospective studies.
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